Skip to main content

Integrated in vitro and in vivo testing of drugs in prion diseases: screening, development and mechanisms of novel therapeutics

Objective

Developing therapeutic strategies for Tees is of great public concern, especially since the advent of variant CJD. We will examine, in a comprehensive and integrate-ed manner, novel candidate drugs targeting different key events in infected pathogen-sis. We will identify compounds that disrupt the structure of prisons (reducing infectivity), inhibit Preps production &/or prevent Induced-induced neurotoxicity. The compounds will then be tested for their ability to inhibit infected replication in lymphoid tissues, block neuroinvasion, inhibit establishment of infection in the CNS &/or retard pathological changes in the brain that lead to clinical disease. These objectives will be attained through combined high throughput in vitro screening systems & defined animal models. Insights into mechanisms of infected disease pathogenesis will be obtained. The outcome will be named compounds that could be used to treat TSE disease in man or inactivate infectivity in biomedical products.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITY OF GLASGOW
Address
Bearsden
G61 1QH Glasgow
United Kingdom

Participants (5)

COMMISSARIAT A L'ENERGIE ATOMIQUE
France
Address
Rue De La Federation 31-33
75015 Paris
ISTITUTO NAZIONALE NEUROLOGICO 'CARLO BESTA'
Italy
Address
Via Celoria 11
20133 Milano
MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH
Italy
Address
Via Eritrea 62
20157 Milano
PEPSCAN SYSTEMS B.V.
Netherlands
Address
Edelhertweg 15
8203 AB Lelystad
VRIJE UNIVERSITEIT AMSTERDAM - VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJS
Netherlands
Address
De Boelelaan 1105
1081 HV Amsterdam